Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial
December 06, 2023 at 01:21 pm EST
Share
(via NewsDirect)
Imugene Ltd (ASX:IMU, OTC:IUGNF) CEO Leslie Chong tells Proactive the company is preparing 10 clinical trial sites in Australia and the UK for a new PD1-Vaxx Phase 2 colorectal (CRC) cancer clinical trial set to begin in 2024. The company intends to enrol 44 patients across the six Australian and four UK sites, to participate in the study for about 18 months. The primary objective of the trial is to determine major pathological response rates, a measurement of tumour size, after treating with PD1-Vaxx but before surgery to remove any residual tumour – also known as neoadjuvant in operable CRC cancer patients.
“We are excited to commence this important Phase 2 trial with PD1-Vaxx after being approached by the leading colorectal cancer oncologists from both Australia and the UK," Chong said. "The study costs are partially funded being Investigator Sponsored studies, and fall within current cash flow forecasts.”
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyâs immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.